Dillard’s Inc. [NYSE: DDS] traded at a high on 01/27/21, posting a 19.82 gain after which it closed the day’ session at $104.46. The company report on January 25, 2021 that PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo Therapeutics Inc. Who Recently Received Orphan Drug Designation from FDA for Esophageal Cancer.
Toronto, Ontario–(Newsfile Corp. – January 25, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, announced that it has entered into the definitive agreement in respect of the previously announced (see press release dated January 12, 2021) proposed acquisition of Sairiyo Therapeutics Inc. (“Sairiyo”) on January 12, 2021. Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise.
Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration (“FDA”) approval. Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. Research and development efforts will be led by Dr. Paul Van Slyke. Dr. Van Slyke is a biotechnology entrepreneur, scientist, and serial inventor. A previous biotech co-founder and Chief Scientific Officer, Dr. Van Slyke brings to Sairiyo a breadth of experience in preclinical and IND-enabling activities. Paul’s previous research interests, complementary to those of Sairiyo, span a number of indications including acute respiratory distress syndrome, acute kidney injury, vascular inflammatory disease, sepsis and oncology. More information about Sairiyo is available on the company’s website which is located at www.sairiyothera.com.
The results of the trading session contributed to over 1243447 shares changing hands. Over the past one week, the price volatility of Dillard’s Inc. stands at 13.46% while the volatility over the past one month is 9.40%.
The market cap for DDS stock reached $2.22 billion, with 22.26 million shares outstanding and 13.26 million shares in the current float. Compared to the average trading volume of 406.42K shares, DDS reached a trading volume of 1243447 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Dillard’s Inc. [DDS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DDS shares is $49.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DDS stock is a recommendation set at 3.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for Dillard’s Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on January 21, 2021. While these analysts kept the previous recommendation, Telsey Advisory Group raised their target price from $30 to $34. The new note on the price target was released on August 14, 2020, representing the official price target for Dillard’s Inc. stock. Previously, the target price had yet another drop from $38 to $30, while Telsey Advisory Group kept a Market Perform rating on DDS stock. On February 26, 2020, analysts decreased their price target for DDS shares from 80 to 65.
The Average True Range (ATR) for Dillard’s Inc. is set at 6.71, with the Price to Sales ratio for DDS stock in the period of the last 12 months amounting to 0.46. The Price to Book ratio for the last quarter was 1.68, with the Price to Cash per share for the same quarter was set at 2.88. Price to Free Cash Flow for DDS in the course of the last twelve months was 12.30 with Quick ratio for the last quarter at 0.30.
How has DDS stock performed recently?
Dillard’s Inc. [DDS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 51.04. With this latest performance, DDS shares gained by 88.79% in over the last four-week period, additionally plugging by 337.07% over the last 6 months – not to mention a rise of 50.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DDS stock in for the last two-week period is set at 87.40, with the RSI for the last a single of trading hit 91.69, and the three-weeks RSI is set at 83.54 for Dillard’s Inc. [DDS]. The present Moving Average for the last 50 days of trading for this stock 56.88, while it was recorded at 83.54 for the last single week of trading, and 37.89 for the last 200 days.
Dillard’s Inc. [DDS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Dillard’s Inc. [DDS] shares currently have an operating margin of +2.64 and a Gross Margin at +29.71. Dillard’s Inc.’s Net Margin is presently recorded at +1.75.
Return on Total Capital for DDS is now 7.47, given the latest momentum, and Return on Invested Capital for the company is 4.97. Return on Equity for this stock inclined to 6.73, with Return on Assets sitting at 3.20. When it comes to the capital structure of this company, Dillard’s Inc. [DDS] has a Total Debt to Total Equity ratio set at 37.88. Additionally, DDS Total Debt to Total Capital is recorded at 27.48, with Total Debt to Total Assets ending up at 17.93. Long-Term Debt to Equity for the company is recorded at 36.91, with the Long-Term Debt to Total Capital now at 26.77.
Reflecting on the efficiency of the workforce at the company, Dillard’s Inc. [DDS] managed to generate an average of $2,923 per employee. Receivables Turnover for the company is 132.13 with a Total Asset Turnover recorded at a value of 1.83.Dillard’s Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 1.70.
Earnings analysis for Dillard’s Inc. [DDS]
With the latest financial reports released by the company, Dillard’s Inc. posted 2.4/share EPS, while the average EPS was predicted by analysts to be reported at 3.01/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -20.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DDS.
Insider trade positions for Dillard’s Inc. [DDS]
There are presently around $1,434 million, or 94.60% of DDS stock, in the hands of institutional investors. The top three institutional holders of DDS stocks are: NEWPORT TRUST CO with ownership of 7,420,197, which is approximately 0.836% of the company’s market cap and around 18.50% of the total institutional ownership; DIMENSIONAL FUND ADVISORS LP, holding 1,400,070 shares of the stock with an approximate value of $122.06 million in DDS stocks shares; and LSV ASSET MANAGEMENT, currently with $84.82 million in DDS stock with ownership of nearly -3.341% of the company’s market capitalization.
Positions in Dillard’s Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 53 institutional holders increased their position in Dillard’s Inc. [NYSE:DDS] by around 903,222 shares. Additionally, 86 investors decreased positions by around 2,641,949 shares, while 25 investors held positions by with 12,908,984 shares. The mentioned changes placed institutional holdings at 16,454,155 shares, according to the latest SEC report filing. DDS stock had 24 new institutional investments in for a total of 429,014 shares, while 33 institutional investors sold positions of 630,738 shares during the same period.